

## This week in techniques

Approach	Summary	Licensing status	Publication and contact information
<b>Drug platforms</b>			
Recombinant meganucleases to treat genetic diseases	Recombinant meganucleases may be useful for treating diseases caused by single-gene mutations. The DNA-binding region of the meganuclease I-Cre was modified to target the <i>xeroderma pigmentosum, complementation group C (XPC)</i> gene. <i>In vitro</i> and in a CHO cell gene-targeting assay, two modified meganucleases exhibited nuclease activity against <i>XPC</i> with less off-target DNA cleavage compared with that seen using zinc-finger nucleases or a low-specificity meganuclease. Next steps include evaluating the engineered meganucleases in animal models.	Engineered meganucleases are patented; available for licensing from Collectis S.A.	Redondo, P. <i>et al. Nature</i> ; published online Nov. 5, 2008; doi:10.1038/nature07343 <b>Contact:</b> Guillermo Montoya, Spanish National Cancer Center, Madrid, Spain e-mail: <a href="mailto:gmontoya@cniio.es">gmontoya@cniio.es</a>
	<i>SciBX</i> 1(41); doi:10.1038/scibx.2008.1010 Published online Nov. 13, 2008		